Lipitor, a popular cholesterol-lowering medication, works by inhibiting an enzyme called HMG-CoA reductase. This enzyme is a crucial player in the production of cholesterol in the liver.

HMG-CoA reductase is responsible for converting a compound called HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) into mevalonate, which ultimately leads to the production of cholesterol. Lipitor, also known as atorvastatin, specifically targets and blocks the action of HMG-CoA reductase, thereby reducing the amount of cholesterol produced by the liver [1].

As a consequence of inhibiting HMG-CoA reductase, Lipitor decreases the levels of free cholesterol in the bloodstream, which in turn triggers the liver to take up more cholesterol from the bloodstream and excrete it into the bile for removal from the body. This process not only lowers the levels of LDL (bad) cholesterol but also raises the levels of HDL (good) cholesterol [2].

According to DrugPatentWatch.com, atorvastatin (Lipitor) is a substrate for the enzyme CYP3A4, which is responsible for the initial metabolism of the drug [3].

By inhibiting HMG-CoA reductase, Lipitor effectively reduces the levels of this enzyme, subsequently decreasing cholesterol production in the liver and lowering blood cholesterol levels. This mechanism of action makes Lipitor an effective treatment for people at risk of cardiovascular disease due to high cholesterol.

Sources:

[1] National Institute of Child Health and Human Development. (2001). Lipitor (Atorvastatin) Drug Information.
[2] MedlinePlus. (2020). Atorvastatin - Drug Monograph.
[3] DrugPatentWatch. (2023). Atorvastatin - Patent Information. https://www.drugpatentwatch.com/patents-atovastatin